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Summary
A subunit protein vaccine candidate based on norovirus (NoV) virus-like
particles (VLPs) and rotavirus (RV) VP6 protein against acute childhood
gastroenteritis has been proposed recently. RV VP6 forms different
oligomeric nanostructures, including tubes and spheres when expressed in
vitro, which are highly immunogenic in different animal models. We have
shown recently that recombinant VP6 nanotubes have an adjuvant effect on
immunogenicity of NoV VLPs in mice. In this study, we investigated if the
adjuvant effect is dependent upon a VP6 dose or different VP6 structural
assemblies. In addition, local and systemic adjuvant effects as well as
requirements for antigen co-delivery and co-localization were studied. The
magnitude and functionality of NoV GII.4-specific antibodies and T cell
responses were tested in mice immunized with GII.4 VLPs alone or different
combinations of VLPs and VP6. A VP6 dose-dependent adjuvant effect on
GII.4-specific antibody responses was observed. The adjuvant effect was
found to be strictly dependent upon co-administration of NoV GII.4 VLPs
and VP6 at the same anatomic site and at the same time. However, the
adjuvant effect was not dependent on the types of oligomers used, as both
nanotubes and nanospheres exerted adjuvant effect on GII.4-specific
antibody generation and, for the first time, T cell immunity. These findings
elucidate the mechanisms of VP6 adjuvant effect in vivo and support its use
as an adjuvant in a combination NoV and RV vaccine.
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Introduction
Noroviruses (NoV) and rotaviruses (RV) are the most com-
mon causes, at a very young age, of childhood viral gastro-
enteritis (GE) worldwide [1–3]. To eliminate the high risk of
NoV and RV-caused gastroenteritis (GE), a vaccination soon
after birth would be needed. Nevertheless, NoV infections
and disease are not yet preventable by vaccination, although
NoV virus-like particles (VLPs)-based vaccines are being
studied extensively. NoV VLPs are non-infectious self-
assembled particles composed of VP1 capsid protein, highly
resembling intact virions both structurally and antigenically
[4]. Currently used RV vaccines are based on live attenuated
viruses [5,6] that are associated with potential safety issues,
such as a risk of intussusception [7] and shedding and trans-
mission of the vaccine strains and reassortment to yield
more virulent forms [8], supporting the need for non-live
RV subunit vaccines. Our group has recently developed a
combination vaccine candidate against NoV and RV child-
hood GE consisting of NoV VLPs and RV VP6 [9,10]. The
combination vaccine induced strong type-specific and cross-
reactive humoral and cellular immunity against NoV and
RV in a mouse model [9,11–13].
In general, highly purified subunit vaccines with the best
safety profile have poor immunogenicity, and the magnitude
and quality of the immune responses need to be enhanced
by adjuvants [14]. However, due to the vulnerability of
infants and young children, it would be highly desirable to
have an efficient vaccine without adding external adjuvants
[15,16]. To this end, we have shown that RV VP6 not only
induced protective immunity against live RV challenge in
mice [13], but it also acted as a strong in-vivo adjuvant on
the generation of antibodies specific for NoV [17].
In a triple-layered RV particle the intermediate layer is
formed by the VP6 protein (45 kD), situated between the
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outermost layer consisting of VP4 and VP7 proteins and
the inner core protein VP2, which surrounds the double-
stranded genome of RV [6,18,19]. RV VP6 is the most
abundant and immunogenic RV protein [20,21], which is
highly conserved among RV strains [22,23]. VP6 forms
trimers organized into hexagons and packed into higher-
order structural assemblies, e.g. VP6 nanotubes (VP6T)
and nanospheres (VP6S), when expressed in vitro
[12,24–27] under different conditions [25,28]. The rVP6 is
highly immunogenic [9,12,29], and it has also been used as
a carrier or delivery platform for heterologous protein anti-
gens and genetically fused epitope-based vaccines, with
improved response to the foreign antigen [30–34]. VP6 is
stable at different pH conditions, and when delivered orally
it was targeted to intestinal cells, offering a promising new
delivery platform to transport pharmaceutical compounds
to gastrointestinal tract [35].
In order to elucidate the mechanisms of VP6 adjuvant
action, we have shown previously that VP6T are taken up
efficiently by macrophages and dendritic cells (DC) in vitro,
resulting in activation and maturation of these antigen-
presenting cells (APC). Also, VP6T were shown to facilitate
the internalization of co-delivered NoV VLPs to the APC
[36]. We undertook the present study to investigate
requirements for co-localization and co-delivery of the
rVP6 with the NoV VLPs in vivo and whether VP6 works
as a local or systemic adjuvant. In addition, adjuvant effect
of VP6T was compared to VP6S.
Materials and methods
Recombinant proteins
NoV VLPs and RV VP6 oligomeric proteins were produced
in a baculovirus–insect cell expression system, as described
in detail elsewhere [9,12,37]. NoV GII.4-1999 VLPs
(GenBank reference strain, Accession number AF080551)
and rVP6 antigens (Accession no. GQ477131) used for
immunizations of animals were highly purified with multi-
step chromatographic procedures or various steps of ultra-
filtration, as described previously [17,38]. The purified
rVP6 was assembled into nanotubes in phosphate-buffered
saline (PBS) at pH 73–75 (Lonza, Verviers, Belgium) or
nanospheres in a 50 mM sodium acetate buffer with
130 mM NaCl, pH 482 [38]. The concentration of the pro-
teins was determined using Pierce BCA protein assay
(Thermo Scientific, Waltham, MA, USA). The purity of the
proteins was verified by Quant-it dsDNA Broad-Range
Assay Kit (Invitrogen, Carlsbad, CA, USA; < 10 ng
dsDNA/10 lg of protein), sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE), BacPAK Rap-
idTiter Kit [Clontech Laboratories, Mountain View, CA,
USA; 0 plaque-forming units (pfu) live BV/ml] and limulus
amebocyte lysate assay (Lonza, < 01 endotoxin units/100
lg of protein), as described in detail elsewhere [9,38]. The
VLPs and oligomeric rVP6 nanostructures used for immu-
nizations were confirmed by negative-staining transmission
electron microscopy (TEM) using an FEI Tecnai F12
(Philips Electron Optics, Eindhoven, the Netherlands) after
negative staining with 3% uranyl acetate pH 46 for protein
morphology and integrity (Fig. 1a–c). NoV VLPs used for
enzyme-linked immunosorbent assay (ELISA)-based ana-
lytical methods, GII.4-1999, GII.4 New Orleans (NO) 2009
(Accession no. GU445325) and GII.4 Sydney (SYD) 2012
(Accession no. AFV08795.1) were purified using sucrose
gradient ultracentrifugation, as described elsewhere [37].
Synthetic peptides and viruses
For quantification of NoV-specific T cell responses by
enzyme-linked immunospot (ELISPOT), an interferon
(IFN)-g assay GII.4 peptide pool (Synpeptide Co. Ltd,
Shanghai, China) containing 76 synthetic peptides [18-
mers, 11 amino acid (aa) overlap], spanning the entire
539aa sequence of GII.4-1999 NoV VP1 [39], was used.
VP6-specific BALB/c mouse (H-2d) CD41 T cell epitope
242DGATTWYFNPVILRPNNV259 [11,40], named R6-2,
was synthetized (Proimmune Ltd, Oxford, UK) and used
Fig. 1. Structure and integrity of the proteins. Electron microscopy images of baculovirus–insect cell system-produced norovirus (NoV) GII.4-1999
virus-like particles (VLPs) (a), rotavirus (RV) VP6 nanotubes (b) and VP6 nanospheres (c) examined by FEI Tecnai F12 electron microscope (Philips
Electron Optics) after negative staining with 3% uranyl acetate, pH 46. Images observed at 323 000 (a,c) or 36800 (b) magnification.
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in RV VP6-specific ELISPOT assays. Ovalbumin (OVA)
323–339 chicken egg albumin peptide (aa 323ISQAVHAA-
HAEINEAGR339, cat. #vac-isq; Invivogen, San Diego, CA,
USA) served as a negative control.
For RV-specific ELISPOT assays human RV strains Wa
(G1P1A[8]) and bovine RV strain WC3 (G6P7[5]) were
propagated in fetal rhesus monkey kidney (MA104) cells,
as described previously [12], and Ridascreen
VR
Rotavirus kit
(R-Biopharm AG, Darmstadt, Germany; cat. C0901) with
the internal rVP6 standard was used to determine the VP6
amount (ng/ml) in the cultures.
Immunization of animals
Female 7–8-week-old BALB/c mice obtained from Envigo
Laboratories (Horst, Limburg, the Netherlands) were
divided to nine groups (groups I–IX) and immunized
intramuscularly (i.m.) at study weeks 0 and 3 with different
doses of antigens diluted in 50 ml PBS, as shown in Table 1.
A minimum of five mice in each group was used. All anti-
gens were delivered into the right thigh muscle of each
mouse except group VI, which received GII.4 VLPs at the
right thigh and VP6T at the contralateral left limb site at
the same time. For immunizing groups II–IV and VII, the
VLPs and VP6 were mixed prior to administration. To
define the temporal requirements of VP6 adjuvant activity,
mice in group V received 10 mg VP6T first, followed by 03
mg VLP 1 h later at the same site. Naive mice receiving car-
rier only (group IX) were used as negative controls. Ani-
mals were anaesthetized before immunization with
sevoflurane inhalate and for euthanasia with a mixture of
medetomidine (Dorbenevet, 1 mg/ml; Laboratorios SYVA
SA, Leon, Spain) and ketamine (Ketaminol vet, 50 mg/ml;
Intervet International BV, Boxmeer, the Netherlands).
Blood and spleens were collected at the time of termination
(at week 5) for the analysis of serological and cell-mediated
immune responses, as described previously [41]. Serum
samples were stored at 2208C, and spleen cell suspensions
were stored in liquid nitrogen before use in the assays. All
mice used were negative for NoV GII.4-specific immuno-
globulin (Ig)G antibodies prior to the immunizations at
week 0 (data not shown). Mice welfare was monitored
throughout the study and experiments were performed in
accordance with the guidelines of the Finnish National Ani-
mal Experiment Board.
Serum IgG antibody ELISA
Sera of immunized and control mice were analysed indi-
vidually by ELISA to determine NoV GII.4-1999, GII.4-
NO, GII.4 SYD and rVP6-specific IgG, IgG1 and IgG2a
titres, as described previously [9,11]. Briefly, 96-well plates
(Corning Inc. Corning, NY, USA) were coated with 50 ng/
well of NoV VLPs or rVP6 in PBS. Duplicates of twofold
serial dilutions of serum samples were incubated for 2 h at
room temperature and bound antibodies were detected
with horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (Sigma-Aldrich, St Louis, MO, USA), IgG1
(Invitrogen) or IgG2a (Invitrogen). Optical density (OD)
at 490 nm was measured by a microplate reader Victor2
1420 (Perkin Elmer, Waltham, MA, USA) and a sample was
considered positive if the OD was above the mean OD of
control mice 13 standard deviations (s.d.) and > 01. End-
point titres were expressed as the highest serum dilution
giving a positive reading.
Blocking assay (a surrogate neutralization assay)
To examine the ability of serum antibodies to block the
binding of NoV VLPs to a putative cellular histo-blood
group antigen (HBGA) receptor, two different sources of
HBGAs, pig gastric mucin (PGM) type III (Sigma Chemi-
cals, St Louis, MO, USA) and human type A saliva were
utilized [42,43]. The blocking assays were conducted with
the procedures described in detail elsewhere [44]. Briefly,
groupwise pooled twofold serum dilutions were preincu-
bated with the 01 mg/ml GII.4-1999 VLPs and the mixtures
were added to 96-microwell plates coated with 25 mg/ml
PGM or 1 : 3000 diluted human type A saliva. Maximum
Table 1. Experimental and control immunization groups
Group Dose of GII.4 VLP Dose and form of rVP6 Administration
I 03 mg – i.m.
II 03 mg 1 mg VP6T i.m., co-administration
III 03 mg 10 mg VP6T i.m., co-administration
IV 03 mg 30 mg VP6T i.m., co-administration
V 03 mg 10 mg VP6T i.m., VP6 first followed by
the VLP after 1 h
VI 03 mg 10 mg VP6T i.m., left tight VP6, right tight
VLP, at the same time
VII 03 mg 10 mg VP6S i.m., co-administration
VIII 3 mg – i.m.
IX (Ctrl) – – i.m., carrier only (PBS)
VLP5 virus-like particle; rVP65 recombinant VP6; i.m.5 intramuscular; VP6T5VP6 nanotubes; VP6S5VP6 nanospheres; Ctrl5 control;
PBS5phosphate-buffered saline.
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VLP binding signal (OD) was determined in wells lacking
serum. The bound VLPs were detected using human anti-
NoV detection serum and anti-human IgG conjugate
(Novex; Thermo Fisher Scientific, Fremont, CA, USA).
Blocking index was calculated as follows: 100%2 [OD
(wells with serum)/OD (wells without serum, maximum
binding)] 3 100%. Results are expressed as the blocking
titre 50 (BT50), a serum titre blocking  50% of the VLPs
binding to the HBGAs [45].
Norovirus-specific ELISPOT IFN-g
To quantify NoV GII.4-specific IFN-g-producing T cells of
immunized mice, an ELISPOT assay was used [11]. Spleno-
cytes from either individual or groupwise pooled mice were
plated on MultiScreenHTS-IP filter plates (Millipore, Biller-
ica, MA, USA) coated with an anti-mouse IFN-g monoclo-
nal antibody (Mabtech AB, Nacka Strand, Sweden) at 5 mg/
ml and blocked with 10% fetal bovine serum (FBS; Sigma-
Aldrich). Cells were stimulated with GII.4-99 peptide pool
(2 mg/ml), GII.4-99 VLPs (5 mg/ml) or OVA peptide (nega-
tive control, 4 mg/ml). Cells incubated in culture medium
(CM) only (RPMI 1640 supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
50 mM 2-mercaptoethanol and 2 mM L-glutamine; Sigma-
Aldrich) and cells were stimulated with 10 mg/ml of T cell
mitogen concanavalin A (ConA; Sigma-Aldrich, cat. C5275)
served as a background and viability control. After overnight
incubation (16–20 h) IFN-g was detected with biotinylated
anti-mouse IFN-g monoclonal antibody (Mabtech AB, cat.
3321–6) and streptavidin–alkaline phosphatase (ALP) conju-
gate (Mabtech AB, cat. 3310–10). The spots were developed
with BCIP/NBT (5-bromo-4-chloro-3-indolyl-phosphate)
substrate (Mabtech AB, cat. 3650–10) and counted by
ImmunoSpot
VR
automatic CTL analyser (CTL-Europe
GmbH, Bonn, Germany). The results were expressed as
mean spot-forming cells (SFC)/106 splenocytes of duplicate
wells. A positive result was considered as an increase of twice
or more above the control antigen SFC counts. Background
counts never exceeded 20 SFC/106 cells.
RV VP6-specific IFN-g and IL-4 ELISPOT
VP6-specific IFN-g and interleukin (IL)-4 T cell responses
were tested using an ELISPOT assay stimulating the spleno-
cytes of immunized and control mice with rVP6 protein (5
mg/ml), R6-2 peptide (5 mg/ml), RV Wa, RV WC3 (05 mg
VP6/ml) or MA104 mock antigen. IFN-g ELISPOT assay
was performed similarly to NoV-specific ELISPOT IFN-g, as
described above. For quantification of IL-4 production the
MultiScreenHTS-IP filter plates were coated with anti-
mouse IL-4 monoclonal antibody (Mabtech AB, cat. 3311-3)
at 5 mg/ml. Groupwise pooled cells were plated and incu-
bated with the antigens for 40–45 h. Biotinylated anti-mouse
IL-4 antibody (Mabtech AB, cat. 3311-6) followed by incu-
bation with streptavidin–ALP and BCIP/NBT substrate were
used for developing the spots. The spots were counted and
the results were expressed as described above.
Statistics
The statistical differences between independent groups
were assessed by Mann–Whitney U-test for serum IgG end-
point titres and ELISPOT assay results. Wilcoxon’s signed-
rank test for comparing two related samples was used for
analysing the difference between IgG1 and IgG2a end-point
titres. Statistical analyses were performed using IBM SPSS
statistics (SPSS, Chicago, IL, USA) version 23. P< 005 was
considered statistically significant.
Results
VP6 adjuvant effect on NoV-specific serum antibody
responses is dose-dependent
In order to determine the mechanism of adjuvant effect of
RV VP6 on NoV-specific antibody responses, mice were
immunized with a suboptimal dose (03 lg) of GII.4-1999
VLP alone or co-administered with different doses of
rVP6T. Immunization with 03 mg GII.4 VLP did not elicit
a significant serum IgG response, whereas co-
administration of 03 mg GII.4 VLP with 10 mg VP6T
resulted in robust NoV-specific serum IgG levels (Fig. 2a),
confirming our previous observation [17]. The GII.4-spe-
cific serum IgG titres were similar (P5 0853) to the titres
obtained with a 3 lg dose of GII.4 VLP alone used as a pos-
itive control (Fig. 2a, group VIII). A 1 lg dose of VP6T co-
administered with 03 lg GII.4 VLP induced lower anti-
body responses than a 10 lg dose of VP6T (Fig. 2a, groups
II and III, P< 001), while a 30 lg dose induced similar
responses (Fig. 2a, groups III and IV, P5 0425), indicating
that the VP6 adjuvant effect was dose-dependent, but pla-
teaued after maximum effect.
VP6 adjuvant effect on NoV-specific serum antibody
responses is local and requires co-delivery
The spatial and temporal requirements of rVP6 adjuvant
activity were next evaluated. A requirement for co-
administration of 03 mg GII.4 VLP1 10 mg VP6T was
tested by delivering antigens at the same time as a mixture
(Table 1, group III), delivering the VLPs 1 h following the
VP6T at the same site (Table 1, group V) or delivering anti-
gens at the same time at the contralateral sites (Table 1,
group VI). Co-administration as a mixture induced signifi-
cantly higher serum NoV GII.4-specific IgG than injecting
VP6T and GII.4 VLPs separately into the same site with 1 h
difference (Fig. 2a, groups III and V, P5 0005). Remark-
ably, no VP6 adjuvant effect on GII.4-specific serum IgG
was seen when the antigens were spatially dissociated
(Fig. 2a, groups III and VI, P< 0005). Hence, the adjuvant
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effect of rVP6 is apparently exerted locally at the site of
administration and not systemically.
VP6 adjuvant effect on NoV-specific serum antibody
responses is not dependent upon the type of
oligomeric structures
We further determined if there is a difference in VP6 adju-
vant effect induced with VP6T or VP6S, as both tubular as
well as spherical structures were shown previously to be
highly immunogenic in mice [12]. When 10 lg VP6S were
co-delivered with the VLPs instead of the VP6T,
comparable IgG titres were observed (P5 0211) (Fig. 2a),
indicating that both oligomeric conformational structures
of rVP6 have comparable adjuvant ability. All negative con-
trol mice receiving PBS only were negative for NoV GII.4-
specific antibodies (data not shown).
VP6 promotes unbiased Th1/Th2-type responses
To determine if the rVP6 has an adjuvant effect on NoV
GII.4-specific T helper type 1 (Th1)-type and/or Th2-type
responses, experimental groups where the VP6 adjuvant
effect was seen (Fig. 2a, groups III, IV and VII, respectively)
Fig. 2. GII.4 genotype-specific immunoglobulin (Ig)G antibody titres. IgG (a), IgG1 (b) and IgG2a (c) end-point titres were determined from
individual, serially diluted sera of immunized mice in enzyme-linked immunosorbent assay (ELISA). Bars represent log10 geometric mean titres
with 95% confidence intervals. For negative mice sera, an arbitrary titre of 1 : 100 (half the starting serum dilution, 1 : 200) was assigned.
*Significantly different (P< 005) antibody titres compared to group III (a) or compared to group I (b,c).
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were tested for GII.4-specific IgG1 and IgG2a antibody
subtypes. Both GII.4-specific IgG1 (Fig. 2b) and IgG2a
antibodies (Fig. 2c) were detected congruently to the IgG
responses seen in Fig. 2a, with significantly higher end-
point titres induced when VP6 was co-administrated with
03 mg VLP (P< 005 for all). There were no significant dif-
ferences in the subtype-specific serum end-point titres
observed (P5 0125), indicating balanced Th1- and
Th2-type responses.
VP6 adjuvant effect on NoV-specific cross-reactive
and blocking antibodies
The VP6 adjuvant effect on cross-reactive serum IgG titres
against two different variants of NoV GII.4 VLPs, GII.4
NO-2010 and GII.4 SYD-2012 VLPs was also investigated
(Fig. 3). Cross-reactive IgG antibodies following immuni-
zation with 03 mg GII.4 VLPs were improved significantly
(P< 0005) by co-administration with 10 mg (group III) or
30 lg (group IV) of VP6T or 10 lg VP6S (group VII). The
VP6 adjuvant effect on NoV GII.4-specific blocking anti-
bodies was investigated further. Human type A saliva and
PGM were used as the HBGA sources for NoV GII.4 VLP
binding. There was no VLP binding blocking (BT50 5 25)
by the mouse sera immunized with the suboptimal 03 lg
dose of VLP alone (Table 2). When VLPs were co-
administrated with 10 or 30 lg of VP6T or VP6S, BT50 of
100–200 were observed (Table 2). As expected, due to the
lack of GII.4-specific serum antibodies, the 10 mg of VP6T
Fig. 3. Norovirus (NoV) cross-reactive immunoglobulin (Ig)G antibodies. Individual, serially diluted sera of immunized mice were analysed for
cross-reactive anti-GII.4 New Orleans (NO) and anti-GII.4 Sydney (SYD) IgG end-point titres. An arbitrary end-point titre of 50 (half the
starting dilution, 1 : 100) was assigned for negative mice sera. Bars represent log10-expressed geometric mean titres of each group with 95%
confidence intervals. *Significantly different (P< 005) antibody titres compared to group III.
Table 2. Blocking antibody titres in immunized mouse sera
Group Immunization
Saliva HBGA PGM HBGA
BT50 BT50
I 03 mg VLP 25a n.t.
II 03 mg VLP1 1 mg VP6T 50 50
III 03 mg VLP1 10 mg VP6T 200 200
IV 03 mg VLP1 30 mg VP6T 200 100
V 03 mg VLP1 10 mg VP6T (1 h) 50 50
VI 03 mg VLP1 10 mg VP6T
(contralateral sites)
25 n.t.
VII 03 mg VLP1 10 mg VP6S 100 100
VIII 3 mg VLP 400 n.t.
IX (Ctrl) Carrier only (PBS) 25 25
aBT50 of 25 was assigned to samples lacking blocking at a serum dilution 1:50.
HBGA5 histo-blood group antigen; PGM5pig gastric mucin; BT505 titres with 50% blocking of norovirus (NoV) GII.4-1999 VLP binding;
VLP5 virus-like particle; n.t.5not tested; VP6T5VP6 nanotubes; VP6S5VP6 nanospheres; Ctrl5 control; PBS5 phosphate-buffered saline.
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and 03 lg VLP administered at the contralateral site
(group VI) as well as the control group (group IX) did not
induce blocking antibodies (Table 2).
VP6 adjuvant effect on NoV-specific T cell responses
NoV GII.4-specific T cell responses were analysed by stimu-
lating the splenocytes of immunized mice with GII.4-1999-
specific peptide pool and GII.4-1999 VLPs and measuring
IFN-g production in the ELISPOT assay (Fig. 4). Immuni-
zation of mice with a 03 mg dose of GII.4 VLPs alone did
not induce detectable IFN-g production, but when co-
administrated with 10 mg of VP6T or VP6S a considerable
NoV GII.4-specific IFN-g secretion was observed (Fig. 4).
There was no significant difference in the overall IFN-g
production by the T cells of mice immunized with VP6T or
VP6S (P> 0.05). Mice immunized with the 10 mg of VP6T
and 03 lg VLP at the contralateral sites (group VI, Table
1) were negative for all antigens tested in the ELISPOT
IFN-g (data not shown), confirming the local adjuvant
effect of VP6 as seen for the NoV GII.4-specific antibody
responses (Fig. 2a).
RV VP6-specific serum antibody responses
Each group of mice immunized with rVP6 (groups II–VII,
Table 1) at different doses or different oligomeric structures
developed RV VP6-specific serum IgG antibodies, indicat-
ing successful immunization (Fig. 5a). Interestingly, very
high VP6-specific IgG end-point titres (GMT 60887) were
induced in mice immunized with GII.4 VLPs and VP6T at
the contralateral sites (group VI, Table 1), ruling out the
possibility that a lack of VP6 adjuvant effect observed in
Fig. 4. Norovirus (NoV) GII.4-specific interferon (IFN)-g
production by T cells. NoV GII.4-1999-specific peptide pool, GII.4-
1999 virus-like particles (VLPs) and ovalbumin (OVA) peptide
(negative control) were used for stimulating IFN-g production of
the mice immunized with 03 mg VLP alone or co-administrated
with 10 mg rVP6 nanotubes (VP6T) or nanospheres (VP6S).
Negative control mice (Ctrl) were immunized with phosphate-
buffered saline (PBS) only. Results are expressed as the mean spot-
forming cells (SFC) per 106 splenocytes of the duplicate wells with
standard errors of the mean. The experiments were repeated two or
more times with similar results.
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this group might result from an unsuccessful immuniza-
tion with rVP6.
RV VP6-specific T cell responses
ELISPOT IFN-g (a hallmark of a Th1-type response) and
IL-4 (a hallmark of a Th2-type response) were used to ana-
lyse RV VP6-specific T cell responses in splenocytes of
immunized mice to VP6 derived R6-2 peptide epitope, RV
cell culture antigens (Wa and WC3) or rVP6 protein. IFN-
g production to all antigens but to a mock antigen was
detected in mice immunized by co-administration of
03 lg NoV GII.4 VLPs and 10 lg VP6T or VP6S (Fig. 5b).
Immunization with VP6T induced somewhat higher IFN-g
production than VP6S, but the difference was not statisti-
cally significant (P5 0073). When the same cells were
tested for VP6-specific IL-4 production, a robust IL-4
response (up to 1016 SFC/106 cells) was observed in the
group that received 03 mg NoV VLPs co-administered with
10 mg of VP6T (Fig. 5c). IL-4 production was also induced
in the group that received 10 mg of VP6S (Fig. 5c) instead
of VP6T; however, the response was significantly higher in
the group that received VP6T (P5 0.008). No RV VP6-
specific IFN-g or IL-4 was secreted by the splenocytes of
mice immunized with 03 mg GII.4 VLP alone (data not
shown) or the control mice (Fig. 5b,c).
Discussion
We have demonstrated recently an in-vivo adjuvant effect
of VP6T on the immunogenicity of NoV VLPs [17]. In
addition, in-vitro studies have shown that VP6 induces
APC activation and maturation [36]. In the present study,
the mechanism of VP6 adjuvant action was investigated
further to explore the effect of co-localization of the two
antigens, NoV VLPs and rVP6, via co-delivery as a mixture
or as separate injections at the same or contralateral injec-
tion sites.
An adjuvant is defined as a compound that enhances the
immune response to vaccine antigens. The adjuvants may
be regarded as depots or vehicles or/and immunomodula-
tory agents. A depo effect facilitates and improves delivery
of antigens to APCs. We therefore investigated if the VP6
functions as a carrier or delivery vehicle that would necessi-
tate the VLP and rVP6 co-delivery as a mixture, instead of
separate injections. The results demonstrated clearly that
the adjuvant effect of VP6 is strictly dependent upon co-
localization of the VP6 with NoV GII.4 VLPs. To accom-
plish the optimal rVP6 adjuvant effect on NoV VLP immu-
nogenicity it was essential to co-administrate the VP6 with
the NoV VLPs, as both temporal and spatial dissociation of
VP6 and NoV VLPs impaired or completely abolished the
adjuvant effect. A 1-h temporal difference in the adminis-
tration of VP6T and NoV VLPs impaired the adjuvant
effect dramatically, further supporting the role of rVP6 as a
delivery vehicle. It has been published that particulate anti-
gens travel very quickly, in terms of minutes, from the site
of injection to the local lymphoid tissue [46]. Although
this study does not extend to confirm this, the results sug-
gest that RV VP6 and VLPs may form aggregates when co-
formulated, VP6 functioning as a carrier. Indeed, our
recently published results showed that NoV VLP uptake
into the APCs was increased when mixed with the rVP6
[36].
In addition to acting initially as the delivery vehicle for
NoV VLPs the VP6 adjuvant effect is probably enforced
further by APC activation. After being delivered, rVP6 may
induce local cytokine and chemokine production and acti-
vation and maturation of APC at the site, as shown by our
earlier in-vitro studies [36]. Proinflammatory cytokines,
such as tumour necrosis factor (TNF)-a, IL-6, IL-1 and
granulocyte macrophage colony-stimulating factor (GM-
CSF), enhance the adaptive immune response in several
ways, including recruitment of APC at the site of injection,
stimulating their maturation and migration to lymph
nodes (LN) [47,48]. Therefore, the VP6 delivery probably
leads to an increased number of NoV VLP-loaded APCs in
the LN draining the injection site able to activate antigen-
specific T cells. Three types of DCs, conventional and
monocyte-derived in steady state skeletal muscles are
targeted by i.m. immunization, which can encounter the
antigen and migrate to LN [49]. Furthermore, VP6 acti-
vation of T cells in lymphoid tissues induces cytokine
production by these cells, such as the observed IFN-g, a
Th1-type cytokine and IL-4, a Th2-type cytokine. Para-
crine secretion of Th1 and Th2 cytokines by the VP6-
specific T cells is of significance, as these cytokines drive
proliferation and differentiation of co-delivered antigen;
in this case NoV VLPs primed naive B and T lympho-
cytes into memory cells [50,51]. The localized nature of
the VP6 adjuvanticity is supported by the observation
Fig. 5. Rotavirus (RV) VP6-specific antibodies and T cell responses.
VP6-specific immune responses were detected following
immunization with 03 mg norovirus (NoV) GII.4 virus-like particles
(VLPs) together with VP6 nanotubes (VP6T) or nanospheres
(VP6S). Control (Ctrl) mice received phosphate-buffered saline
(PBS) only. (a) Serum anti-VP6 IgG of individual mice were tested
in enzyme-linked immunosorbent assay (ELISA) and the mean
titration curves of each experimental group are shown. Bars
represent log10 geometric mean titres with 95% confidence intervals.
For negative mice sera, an arbitrary titre of 1 : 100 (half the starting
serum dilution, 1 : 200) was assigned. VP6-specific IFN-g (b) and
interleukin (IL)-4 (c) production by T cells was tested stimulating
the cells with VP6-specific R6-2 peptide, RV Wa and WC3 cell
culture antigens, mock antigen or recombinant VP6 protein (rVP6).
Results are expressed as the mean spot-forming cells (SFC)/106
splenocytes of the duplicate wells with standard errors of the mean.
The experiments were repeated two or more times with similar
results.
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that VP6 administration at the contralateral site did not
contribute to the NoV-specific immunity, even though
high VP6-specific immune responses were observed.
Moreover, serum collected at 3 and 24 h post-VP6T
immunization was negative for proinflammatory cyto-
kines TNF-a and IL-6 by ELISA (data not shown),
arguing against a systemic adjuvant effect.
The results of the present study show that rVP6 pro-
motes both Th1- and Th2-type responses to NoV without
skewing the overall immune response in any particular
direction. The adjuvants are mainly restricted to enhance
either type of the responses, such as aluminium salts, which
promote mainly Th2-type responses to the co-
administered vaccine antigens [52]. The particle size and
shape are shown to be central in the antigen internalization
and transport to LN and immune cell activation
[48,53–55]. Additionally, the particle size and shape may
play a role in tuning the adaptive immunity, as rod-shaped
particles have been reported to induce Th2-biased
responses compared to spherical particles [56]. However,
although we observed more IL-4 production by the VP6T-
specific T cells compared to VP6S, both these nanostruc-
tures exerted a similar adjuvant effect on NoV GII.4-spe-
cific antibody responses.
Our results show, for the first time, the VP6 adjuvant
effect on NoV-specific T cell immunity. It has been pub-
lished that VP6 can potentiate the serum antibody response
against RV in a mouse model by an intermolecular help
mechanism [57]. In the present study, as the VP6 is not
conjugated or linked to the VLPs, bystander T cell help is
probably an important mechanism. These cells may drive
proliferation and differentiation of NoV-antigen primed B
and T lymphocytes into memory cells and antibody-
secreting plasma cells either by cell-to-cell contact
(CD40-CD40L interaction) [58] or soluble cytokine pro-
duction [59].
Altogether, this study shows clearly that co-
administration of the VP6 with NoV VLPs is essential for
the optimal adjuvant effect on NoV-specific immune
responses and that the VP6 acts as a delivery vehicle as well
as immunomodulator. Safety is a major concern when it
comes to adjuvant approval for human use, especially for
healthy infants [16]. The results of this study support the
use of rVP6 not only to provide protection against RV in
the proposed NoV VLP–RV VP6 combination vaccine
[9,10], but also as an adjuvant to potentiate the NoV VLP
immunogenicity.
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